Cardiome Pharma Corp Company Profile (TSE:COM)

About Cardiome Pharma Corp (TSE:COM)

Cardiome Pharma Corp logoCardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company's segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD and ESMOCARD LYO (esmolol hydrochloride), a short-acting beta-blocker used to control heart rate in various cardiovascular indications, in select European markets. Cardiome has also licensed TREVYENT, a development-stage drug device combination product that is under development for pulmonary arterial hypertension, in certain regions outside the United States.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: TSE:COM
  • CUSIP: N/A
  • Web: www.cardiome.com/
Capitalization:
  • Market Cap: C$181.66 million
  • Outstanding Shares: 31,927,000
Average Prices:
  • 50 Day Moving Avg: C$5.54
  • 200 Day Moving Avg: C$4.58
  • 52 Week Range: C$3.25 - C$6.06
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.16
Sales & Book Value:
  • Annual Revenue: C$23.37 million
  • Price / Sales: 7.77
  • Book Value: C$0.88 per share
  • Price / Book: 6.47
Profitability:
  • EBIDTA: ($15,620,000.00)
  • Net Margins: -121.81%
  • Return on Equity: -81.68%
  • Return on Assets: -40.03%
Misc:
  • Average Volume: 7,621 shs.
  • Short Ratio: 7.15
 
Frequently Asked Questions for Cardiome Pharma Corp (TSE:COM)

What is Cardiome Pharma Corp's stock symbol?

Cardiome Pharma Corp trades on the Tornton Stock Exchange (TSX) under the ticker symbol "COM."

How were Cardiome Pharma Corp's earnings last quarter?

Cardiome Pharma Corp (TSE:COM) posted its earnings results on Monday, August, 11th. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by $0.10. The company earned $8.40 million during the quarter, compared to the consensus estimate of $7.37 million. Cardiome Pharma Corp had a negative return on equity of 81.68% and a negative net margin of 121.81%. View Cardiome Pharma Corp's Earnings History.

Who are some of Cardiome Pharma Corp's key competitors?

Who are Cardiome Pharma Corp's key executives?

Cardiome Pharma Corp's management team includes the folowing people:

  • W. James O'Shea, Independent Chairman of the Board
  • William L. Hunter M.D., President, Chief Executive Officer, Director
  • Justin A. Renz, Chief Financial Officer
  • Sheila M. Grant, Chief Operating Officer
  • David D. McMasters J.D., Corporate General Counsel
  • David C. Dean, Chief Business Development Officer
  • Jennifer Archibald CPA, Chief Business Operations Officer
  • Hugues Sachot, Chief Commercial Officer
  • Richard M. Glickman LL.D., Lead Independent Director
  • Mark H.N. Corrigan M.D., Independent Director

How do I buy Cardiome Pharma Corp stock?

Shares of Cardiome Pharma Corp and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Cardiome Pharma Corp's stock price today?

One share of Cardiome Pharma Corp stock can currently be purchased for approximately C$5.69.


MarketBeat Community Rating for Cardiome Pharma Corp (TSE COM)
Community Ranking:  3.0 out of 5 (  )
Outperform Votes:  15 (Vote Outperform)
Underperform Votes:  10 (Vote Underperform)
Total Votes:  25
MarketBeat's community ratings are surveys of what our community members think about Cardiome Pharma Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cardiome Pharma Corp (TSE:COM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: N/A

Analysts' Ratings History for Cardiome Pharma Corp (TSE:COM)
Show:
DateFirmActionRatingPrice TargetDetails
5/17/2017HC WainwrightReiterated RatingBuyView Rating Details
11/9/2016Bloom BurtonReiterated RatingBuyView Rating Details
(Data available from 7/26/2015 forward)

Earnings

Earnings History for Cardiome Pharma Corp (TSE:COM)
Earnings by Quarter for Cardiome Pharma Corp (TSE:COM)
Earnings History by Quarter for Cardiome Pharma Corp (TSE COM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/11/2014($0.18)($0.28)$7.37 million$8.40 millionViewN/AView Earnings Details
3/28/2014($0.34)($0.45)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cardiome Pharma Corp (TSE:COM)
2017 EPS Consensus Estimate: ($0.68)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.12)($0.12)($0.12)
Q2 20171($0.22)($0.22)($0.22)
Q3 20171($0.15)($0.15)($0.15)
Q4 20171($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cardiome Pharma Corp (TSE:COM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Cardiome Pharma Corp (TSE:COM)
Insider Trades by Quarter for Cardiome Pharma Corp (TSE:COM)
Insider Trades by Quarter for Cardiome Pharma Corp (TSE:COM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/17/2017Justin RenzInsiderBuy10,000C$3.52C$35,200.00
3/27/2015Sheila GrantInsiderSell1,400C$10.64C$14,896.00
3/16/2015Sheila GrantInsiderSell4,700C$11.87C$55,789.00
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Cardiome Pharma Corp (TSE:COM)
Latest Headlines for Cardiome Pharma Corp (TSE:COM)
Source:
DateHeadline
reuters.com logoBRIEF-Cardiome Pharma announces Health Canada approval of AGGRASTAT high dose bolus regimen
www.reuters.com - July 17 at 11:26 PM
finance.yahoo.com logoResearch Initiated on Healthcare Stocks: Concordia International, ProMetic Life Sciences, Theratechnologies, and Cardiome Pharma
finance.yahoo.com - July 12 at 6:08 PM
nasdaq.com logoCardiome's Partner SteadyMed Submits NDA for PAH Injection - Nasdaq
www.nasdaq.com - July 5 at 4:42 AM
zacks.com logoCardiome's Partner SteadyMed Submits NDA for PAH Injection
www.zacks.com - July 4 at 11:36 PM
streetinsider.com logoCardiome Pharma (CRME) partner SteadyMed Ltd (STY) Submits TREVYENT NDA
www.streetinsider.com - July 3 at 10:24 PM
reuters.com logoBRIEF-Cardiome's partner SteadyMed submits U.S. new drug application for TREVYENT
www.reuters.com - July 3 at 10:24 PM
reuters.com logoBRIEF-Cardiome's partner SteadyMed submits US new drug application for TREVYENT - Reuters
www.reuters.com - July 3 at 5:23 PM
streetinsider.com logoCardiome Pharma (CRME) partner SteadyMed Ltd (STY) Submits TREVYENT NDA - StreetInsider.com
www.streetinsider.com - July 3 at 5:23 PM
finance.yahoo.com logoCardiome's Partner SteadyMed Submits U.S. New Drug Application for TREVYENT® for the Treatment of Pulmonary Arterial Hypertension
finance.yahoo.com - July 3 at 5:23 PM
globenewswire.com logoSteadyMed Submits New Drug Application for Trevyent® Nasdaq ... - GlobeNewswire (press release)
globenewswire.com - June 30 at 10:37 PM
prnewswire.com logoCardiome Pharma Corp. Announces Voting Results - PR Newswire (press release)
www.prnewswire.com - June 23 at 5:03 PM
finance.yahoo.com logoCardiome Pharma Corp. Announces Voting Results
finance.yahoo.com - June 23 at 5:03 PM
reuters.com logoBRIEF-Cardiome announces licensing agreement for xydalba to support planned commercialization in Israel
www.reuters.com - June 22 at 11:00 AM
streetinsider.com logoCARDIOME PHARMA CORP. - StreetInsider.com
www.streetinsider.com - June 21 at 5:37 PM
finance.yahoo.com logoCardiome Announces Licensing Agreement for XYDALBA™ (Dalbavancin Hydrochloride) to Support Planned Commercialization in Israel
finance.yahoo.com - June 21 at 5:37 PM
reuters.com logoBRIEF-Cardiome announces commercial launch of BRINAVESS in Canada - Reuters
www.reuters.com - June 13 at 12:35 PM
reuters.com logoBRIEF-Cardiome announces commercial launch of BRINAVESS in Canada
www.reuters.com - June 12 at 5:24 PM
finance.yahoo.com logoCardiome Announces Commercial Launch of BRINAVESS® (Vernakalant Hydrochloride) in Canada
finance.yahoo.com - June 12 at 5:24 PM
seekingalpha.com logoCardiome Pharma: The Pieces Are Coming Together - Seeking Alpha
seekingalpha.com - May 25 at 6:00 PM
finance.yahoo.com logoEdited Transcript of COM.TO earnings conference call or presentation 15-May-17 8:30pm GMT
finance.yahoo.com - May 21 at 4:18 PM
americanbankingnews.com logoCardiome Pharma Corp (COM) Insider Acquires C$35,200.00 in Stock
www.americanbankingnews.com - May 19 at 4:24 PM
americanbankingnews.com logoHC Wainwright Reaffirms "Buy" Rating for Cardiome Pharma Corp (COM)
www.americanbankingnews.com - May 19 at 7:18 AM
americanbankingnews.com logoCardiome Pharma Corp (COM) Forecasted to Earn Q2 2017 Earnings of ($0.22) Per Share
www.americanbankingnews.com - May 18 at 8:01 AM
streetinsider.com logoCardiome Pharma (CRME) Names Justin Renz as CFO; Jennifer Archibald Appointed Chief Business Operations Officer - StreetInsider.com
www.streetinsider.com - May 16 at 4:27 PM
finance.yahoo.com logoCardiome to Present at the Bloom Burton & Co. 6th Annual Healthcare Investor Conference
finance.yahoo.com - April 27 at 11:23 AM
finance.yahoo.com logoResearch Reports Initiated on Healthcare Stocks: Cardiome Pharma, Immunovaccine, Oncolytics Biotech, and Aeterna Zentaris
finance.yahoo.com - April 26 at 5:27 PM
finance.yahoo.com logoCardiome's Partner SteadyMed Announces Successful Completion of Trevyent® Clinical Validation Study
finance.yahoo.com - April 7 at 9:07 AM
nasdaq.com logoSteadyMed Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
www.nasdaq.com - March 29 at 4:51 PM
reuters.com logoBRIEF-Cardiome receives Notice of Compliance from Health Canada for its BRINAVESS NDS
www.reuters.com - March 14 at 6:27 PM
finance.yahoo.com logoIIROC Trade Resumption - COM
finance.yahoo.com - March 14 at 6:27 PM
reuters.com logoBRIEF-Cardiome Pharma Corp says Q4 loss per share $0.18
www.reuters.com - March 9 at 5:00 PM
reuters.com logoBRIEF-Cardiome Pharma Corp says Q4 loss per share $0.18 - Reuters
www.reuters.com - March 9 at 3:16 AM
biz.yahoo.com logoQ4 2016 Cardiome Pharma Corp Earnings Release - Time Not Supplied
biz.yahoo.com - March 7 at 12:17 PM
finance.yahoo.com logoCardiome Announces Commercial Launch of Xydalba™ (dalbavancin) in France
finance.yahoo.com - March 3 at 4:25 PM
finance.yahoo.com logoCardiome To Hold Fourth Quarter And Full Year 2016 Financial Results Conference Call On March 7 - Yahoo Finance
finance.yahoo.com - March 1 at 4:29 PM
finance.yahoo.com logoCardiome To Hold Fourth Quarter And Full Year 2016 Financial Results Conference Call On March 7
finance.yahoo.com - February 27 at 4:24 PM
nasdaq.com logoSteadyMed Outlines Strategic Goals and Priorities for 2017 and Provides Update on Trevyent Launch Plans
www.nasdaq.com - January 9 at 5:35 PM
streetinsider.com logoForm 6-K Cardiome Pharma Corp For: Dec 20
www.streetinsider.com - December 21 at 5:09 PM
streetinsider.com logoCardiome Pharma (CRME) Initiated Commercial Launch of XYDALB in Germany
www.streetinsider.com - December 20 at 8:50 AM
reuters.com logoBRIEF-Cardiome Pharma announces commercial launch of Xydalba in Germany
www.reuters.com - December 20 at 8:50 AM
finance.yahoo.com logoCardiome Announces Commercial Launch of XYDALBA™ (dalbavancin) in Germany
finance.yahoo.com - December 20 at 8:50 AM
streetinsider.com logoForm 6-K Cardiome Pharma Corp For: Dec 08 - StreetInsider.com
www.streetinsider.com - December 10 at 11:22 AM
reuters.com logoBRIEF-Cardiome Announces Commercial Launch of Xydalba in the UK
www.reuters.com - December 8 at 4:15 PM
streetinsider.com logoCardiome Pharma (CRME) Announces Early Launch of XYDALBA in the U.K.
www.streetinsider.com - December 8 at 4:15 PM
finance.yahoo.com logoCardiome Announces Commercial Launch of Xydalba™ (dalbavancin) in the UK
finance.yahoo.com - December 8 at 4:15 PM
globenewswire.com logoSteadyMed Hires Pulmonary Hypertension Veteran to Lead Patient Advocacy and Community Relations
globenewswire.com - December 7 at 5:03 PM
streetinsider.com logoCardiome Pharma (CRME) Moves Closer to XYDALBA Launch in the UK
www.streetinsider.com - November 30 at 4:31 PM
finance.yahoo.com logoCardiome Advances Toward the UK XYDALBA™ (dalbavancin) Launch
finance.yahoo.com - November 30 at 9:13 AM

Social

Chart

Cardiome Pharma Corp (COM) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by MarketBeat.com Staff